Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Cg Oncology, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

For the Company’s disclosures about market risk, please see “Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk” in our 2025 Annual Report filed with the SEC. There have been no material changes to the Company’s disclosures about market risk in Part II—Item 7A of our 2025 Annual Report.